In patients with systemic lupus erythematosus (SLE), immature B cells that recognize self antigens fail to undergo apoptosis or suppression before maturation; one consequence is that untreated ...

Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...

It is currently being studied for both cutaneous and systemic lupus erythematosus (SLE). Obinutuzumab (Gazyva®) is a treatment that works by blocking the activation of B cells, which contribute to ...

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.

Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.

Systemic lupus erythematosus (SLE, lupus) is characterized by immune cell dysregulation including abnormalities in B lymphocytes, the antibody producing cell lineage of the immune system. In fact, ...

Primary outcome measures were evaluation of frequency and rate of adverse events at 12 and 24 weeks, as well as baseline change in B cell and B-cell ... measures: SS, SLE flare Index (SFI ...

While there is variability between in vitro studies, SLE DCs exhibit an aberrantly mature and activated phenotype. Relationship Between Type I IFN & Dendritic Cells in SLE IFN-α is produced ...

Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.

ADI-001 is an allogeneic gamma delta CAR T-cell therapy that targets the B-cell antigen CD20. The Food and Drug Administration (FDA) has granted Fast Track designation to ADI-001 for the treatment ...